2496 — Wuhan YZY Biopharma Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$911.09m
- HK$912.24m
- CNY107.81m
Annual cashflow statement for Wuhan YZY Biopharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -149 | -189 | -192 | -97.6 |
| Depreciation | ||||
| Non-Cash Items | 53.8 | 3.15 | 1.72 | 0.144 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -11.5 | 2.12 | -3.31 | -9.79 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Prepaid Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -98.7 | -177 | -186 | -101 |
| Capital Expenditures | -1.9 | -1.41 | -1.93 | -1.51 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -18 | 7.21 | 56.7 | -3.16 |
| Sale of Fixed Assets | ||||
| Change in Net Investments | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -19.9 | 5.8 | 54.8 | -4.67 |
| Financing Cash Flow Items | -4.39 | -6.73 | -9.88 | -4.08 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 81 | 241 | 176 | 33 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -37.6 | 70.4 | 43.2 | -70.4 |